yes serious AEs are no different, just things like injection site pain and mild self limiting systemic stuff so that is why I would want the efficacy boost w GSK (which is there despite all the talk about difficult cross trial comparisons)
I just looked it up and shingrix is associated with an excess of 3 cases of GBS per million doses. I wasn’t aware of this. Even though they use a half dose adjuvant for RSV this will be some thing to monitor if approved and given on wide scale (I guess for PFE too since they reported 2 cases in trials now too)
Market Data 
Markets 
AI
